No robust argument
- PMID: 24606782
- PMCID: PMC3950761
- DOI: 10.3238/arztebl.2014.0035b
No robust argument
Comment in
-
In reply.Dtsch Arztebl Int. 2014 Jan 17;111(3):37-8. doi: 10.3238/arztebl.2014.0037b. Dtsch Arztebl Int. 2014. PMID: 24606786 Free PMC article. No abstract available.
Comment on
-
Does the pharmaceutical industry influence guidelines?: two examples from Germany.Dtsch Arztebl Int. 2013 Sep;110(35-36):575-83. doi: 10.3238/arztebl.2013.0575. Epub 2013 Sep 2. Dtsch Arztebl Int. 2013. PMID: 24078837 Free PMC article.
References
-
- TA 103 Etanercept and efalizumab for the treatment of adults with psoriasis. NICE Technology appraisal guidance 103 - Issued: July 2006. http://guidance.nice.org.uk/TA103 (last accessed on 23 September 2013)
-
- About NICE. What we do. Evidence-based guidance and advice. www.nice.org.uk/aboutnice/whatwedo/what_we_do.jsp (last accessed on 23 September 2013)
-
- Leitlinien-Manual von AWMF und der „äzq“. www.awmf.org/leitlinien/awmf-regelwerk/awmf-publikationen-zu-leitlinien/... (last accessed on 23.9.2013)
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources